- Organizations: Alimera
Business
ANI Pharmaceuticals officially acquires Alimera Sciences
Purchase includes YUTIQ and ILUVIEN, expanding the company’s ophthalmic presence in the rare disease space.
Business
ANI Pharmaceuticals to purchase Alimera Sciences
Acquisition expands ANI’s ophthalmic foothold with the addition of two FDA-approved therapeutics: ILUVIEN and YUTIQ.
Pipeline
Enrollment concludes for Alimera's Synchronicity study on Yutiq
Phase 4 trial evaluates intravitreal implant in patients with chronic NIU and related intraocular inflammation
Pipeline
Alimera completes patient enrollment for DME study on ILUVIEN
NEW DAY study is evaluating the intravitreal implant as a baseline therapy compared to aflibercept.
Business